MRC introduces new PowerScribeThe MRC Group unveiled version 2.0 of its PowerScribe for Radiology speech recognition offering at the 1998 Healthcare Information & Management Systems Society (HIMSS) annual meeting. The new version features
The MRC Group unveiled version 2.0 of its PowerScribe for Radiology speech recognition offering at the 1998 Healthcare Information & Management Systems Society (HIMSS) annual meeting. The new version features real-time, workstation-based speech recognition, as well as server-based speech recognition, which maximizes system performance and radiologist acceptance, according to the Cleveland-based company.
Available now, version 2.0 also enables radiologists to dictate and edit the report immediately, according to the firm. In addition, radiologists can navigate and edit their reports by voice. Current PowerScribe for Radiology customers will be upgraded free of charge. MRC developed the PowerScribe family of products in partnership with Articulate Systems of Woburn, MA.
Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.
The Reading Room Podcast: Current and Emerging Insights on Abbreviated Breast MRI, Part 3
August 2nd 2025In the last of a three-part podcast episode, Stamatia Destounis, MD, Emily Conant, MD and Habib Rahbar, MD, share additional insights on practical considerations and potential challenges in integrating abbreviated breast MRI into clinical practice, and offer their thoughts on future research directions.
The Reading Room Podcast: A Closer Look at Remote MRI Safety, Part 3
August 2nd 2025In the third of a three-part podcast episode, Emanuel Kanal, M.D. and Tobias Gilk, MRSO, MRSE, discuss strategies for maintaining the integrity of time-out procedures and communication with remote MRI scanning.
Twenty Years of CT Colonography for Colorectal Cancer Screening: What the Research Reveals
August 2nd 2025Computed tomography colonography (CTC) demonstrated a 91.6 percent positive predictive value (PPV) for polyps > 6 mm, according to new research involving over 9,000 patients who underwent CTC for primary asymptomatic colorectal cancer screening.